Haleon reported first-quarter results below expectations, impacted by subdued demand for over-the-counter cold and flu medications at the start of the year. The company, which produces pain relievers such as Panadol and Advil, announced on Wednesday that first-quarter organic sales increased by 2.2%, missing analysts' expectations of 2.4%. Revenue reached £2.857 billion, representing a marginal year-over-year increase of 0.1%. Haleon had previously cautioned that a weak cold and flu season toward the end of 2025 would extend into the new fiscal year, echoing similar performance reported by its competitor Reckitt Benckiser a week earlier. Reckitt also posted lower-than-expected sales, citing weak demand for its cold and flu medications in the U.S. and supply disruptions in the Middle East due to regional conflicts. Consumer brands are navigating a challenging market environment, compounded by cautious spending in the U.S. and Europe amid rising household bills, supply chain disruptions, and increased energy costs linked to geopolitical tensions. On the London Stock Exchange, Haleon’s share price has declined by 6.4% since the beginning of the year, while Reckitt’s shares have fallen approximately 24%. Haleon has been grappling with weak demand and intense competition in the U.S., its largest market. In response, the company has restructured its leadership and adjusted distribution channels in the region, now anticipating accelerated growth in North America this year. Despite the softness in cold and flu medication sales, other segments of Haleon’s business performed better, with strong demand for its specialized toothpaste brands Sensodyne and Parodontax. Haleon has been actively promoting these toothpaste brands in emerging markets such as China and announced an investment of £65 million (approximately $87.8 million) in the country during the period. The company reaffirmed its outlook for 2026, projecting organic revenue growth of 3–5% and high single-digit growth in adjusted operating profit.